Decision making in NICE single technological appraisals (STAs): How does NICE incorporate patient perspectives? by Hashem, Ferhana et al.
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Hashem, Ferhana and Calnan, Michael .W. and Brown, Patrick R  (2014) Decision making in
NICE single technological appraisals (STAs): How does NICE incorporate patient perspectives?
   In:   Health Policy and Politics Network - Annual Conference.  .
DOI




Hashem F, Calnan M and  Brown P   
*
School of Social Policy, Sociology and Social Research
**Explicit rationing role performed by NICE :  to assure 
the consistently equitable access of patients to drugs 
across the entire NHS /the efficient use of public 
finances by regulating NHS consumption of new 
/expensive drugs via cost-effectiveness criteria 
* Based on rigorous appraisals of scientific evidence, 
NICE seeks to manage uncertainty through a 
calculative and evidence-based approach, as a 
reaction to “the nature of modern culture, especially 
its technical and economic substructure, [which] 
requires precisely such ‘calculability’ of 
consequences” (Weber 1978:351)
* Co-ordinated proceduralism to 'absorb' uncertainty  
and overcome associated arbitrary variations in 
pharmaceutical availability
**The decision-making within NICE technological 
appraisals appears neutral, objective and 
rational - yet there are number of ways in 
which mechanisms of decision-making might be 
influenced by social influences which are 
implicit in  this process (i.e. patient 
perspectives)
*eg confidence is required in research 
paradigms and approaches - trust in weighing 
up the evidence presented by different expert 
patients, leading clinicians, or drug company 
representatives
**Experience of having 
the condition, or 
caring for someone 
with the condition
*Experience of 
receiving care for the 
condition in the HS
*Experience of having 
specific treatments for 
the condition
*Outcomes of treatment 
that are important to 
patients & carers
*Acceptability of 
different treatments & 
modes of treatment
*Preferences for 
different treatments & 
modes of treatment
*Expectations about 
risks & benefits of the 
technology
NICE – Process & Methods 
Guide (2013)
*“…in the context of technological 
appraisals the main purpose of qualitative 
research is to explore areas such as 
patients’ experiences of having a disease 
or condition, their experience of having 
treatment and their views on the 
acceptability of different types of 
treatments”
NICE – Process & Methods Guide (2013)
**epistemic uncertainty – the effectiveness of 
certain methods of investigation to provide 
knowledge about conditions and their treatment 
* interpersonal uncertainty– regarding the 
competency and motives of those providing 
evidence and/or recommendations within the 
process. Focus here will be on
- how Committees incorporate evidence
- dealing with patient experts’ views
- Committee members’ personal 
experience and background
**The study explores the decision-making process 
and more specifically the various ways in which 
different forms of uncertainty -epistemic 
procedural, relational and others were 
perceived, presented and tackled within these 
drug appraisals
**Qualitative, ethnographic research methods: 
data will be collected though three different 
but complementary methods: analysis of 
documents; non participant, unstructured 
observation of meetings; and qualitative, 
informal interviews with key informants 
involved in the appraisal process. 
**This study used a prospective design to follow three 
distinctly different pharmaceutical products 
through the single technology appraisal process in 
three different technological appraisal committees. 
*Products were chosen for variation in the socio-
cultural resonance of the illness they are designed 
to treat and the following were selected :
- a drug treating a high profile type of  cancer 
(Case Study 2) 
- a drug treating a less ‘prominent’ but 
prevalent chronic  illness (Case Study 1) 
- a drug which treated a rare but life-
threatening condition (Case Study 3)
*Telephone 
interview
Face to face Sub-total
Case Study 1 9 5 14
Case Study 2 7 5 12
Case Study 3 10 2 12
Background 
interviews
0 3 Total = 41
**One of the key characteristics of the STA process is 
that it tends to rely  on manufacturer-provided 
information.
*The STA  from start to finish has three distinct 
phases : this  study focused on a significant part of  
the process - starting from directly after the 
teleconference between the TA team and other 
interest groups with an interview with the chair of 
the committee before the first formal meeting 
following through the various committee stages to 
the finalisation of the decision prior to an appeal if 
one was pursued. 
*Three committee meetings were necessary to 
appraise the technology in Case Study 1, two for 
Case Study 2 and five for Case Study 3. 
*The outcomes of the decision-making for each of 
the technologies was a recommendation of a 
conditional ‘yes’ in Case Study 1 and no for the 
technological appraisals in Case study 2 and Case 










Potential points of tension 
/ conflict
**“And I think this is one of the challenges and why 
it’s so amazingly helpful to have people with all 
different perspectives because everybody will have 
their own, not just perspective but their own 
strengths in interpreting the evidence and some 
people will come from, for example lay people, 
with a sort of common sense lay perspective of 
what do they think patients would view their 
informed, fully informed patients in a way” 
Committee Member Clinician
**“Yeah.  So basically around the issues and this 
was a person who clearly benefitted from the 
drug.  She said, “This is my quality of life 
so...” and she seemed quite energetic and so 
NICE were kind of quite... quite... quite...   
Yeah, they were quite taken by how she 
presented herself etc. because, you know, she 
was a patient…”
Committee Member Clinician & Academic
**“I think the committee members deal with it in 
two ways; one… one is completely dismiss the 
emotional arguments and give me the data, you 
know, or completely dominated by do we really 
understand, you know, the burden of this and the 
need for… the unmet need of the treatment and 
that’s kind of, you know, of, you know, the lens by 
which you view the case.  So… so it’s a tricky one.  
You know, it’s not directly part of the QALY or the 
ICER or anything like that but it… but it… you 
know, it does have a role clearly”
Committee Member Health Economist
**“Because, you know, they’re the people who 
are actually suffering and they’re telling you 
what a huge difference it can make to their 
lives or the… the length of time they have left 
so that’s sometimes quite a struggle…So it’s 
hard… it’s hard to keep… to stay neutral, I 
think, at times” 
Committee Member NHS Management 
**“So I can easily imagine that everyone takes their 
own personal background, experience into the 
deliberations so…  The moment that your father has 
exactly that kind of cancer might colour your 
opinions, it’s quite difficult then to stay completely 
objective or, yeah, sometimes I feel that even the 
fact that a certain manufacturer has sort of built 
themselves a reputation for trying to manipulate 
things and not being very straightforward etc. can 
already… they already start in the negative 
basically.  So these kind of things can play a role 
somewhere but it will never be acknowledged 
anywhere…” 
Independent Evidence Reviewer
**"I’ve seen impassioned pleas for drugs that are completely 
ludicrous because the person didn’t have the drug that anyway the 
combination has been discussed, secondly they’ve got a particularly 
difficult case and they’ve been selected for that reason so...   But I 
mean...  So I don’t...  I don’t think that the patient representative 
is necessarily ever very illuminating.  I think what it  is sometimes 
it’s a condition you don’t know about and not in this one and the 
patient just says what the... is telling the committee what the 
disease means. And in that respect that can be quite a useful thing”
Committee Member Clinician
**“It appears that many of these companies support these support 
groups and help groups and at the beginning of every meeting 
everyone declares a conflict of interest and things like that.. I’ve 
certainly been aware of it once where it was quite clear that a 
company was heavily supportive of the particular sort of patient 
support group and I found that quite difficult to be completely 
objective about… because sometimes the drug companies might 
take… or maybe the patients might be a bit naïve about some of 
the motivation but I think it is something you can’t really ignore… 
And that has crossed my mind a few times that, you know, that 
there may be a tighter relationship than is evident and it’s partly 
because sometimes on their way into the building, you know, we go 
into the building and up the stairs and the public and the others 
are all clustered down the stairs and they’re brought in and they 
sit, you know, up at the back and everything and you can’t help but 
notice engagement, you know, at that kind of social level”
Committee Member Clinician
*“Also the chair felt it was not innovative although felt the 
need to mention that one of the charities saw it as ‘ground 
breaking’ as the CM did not want to be accused of not taking 
the patient experts seriously…”
Observation notes Case study 2
**“No.  I… I really felt that second time I interrupted 
about the XXXXX surgery, the patient experts really 
you could have almost said we… we weren’t needed 
there” Patient Expert
*The second meeting I…  No, I didn’t feel that…  I 
didn’t…  I think it was slightly unusual circumstances 
that I was invited back to the second meeting because 
you wouldn’t normally be invited back…And I felt that 
I wasn’t asked many questions, which was fine but I 
didn’t really feel I needed to be there…I don’t think I 
really… me being there really added anything to 
proceedings” Patient Expert
**NICE Committee members grapple with 
assessing clinical / cost effectiveness data 
while incorporating patient perspectives in 
STAs
*Decision-making in STAs is far from an 
objective & neutral process – layers of social 
influences from patient perspectives, personal 
interpretations / views from Committee 
members
*Question arises around how much Committee 
members take on board the views of 
patients/carers in decision making
